title: Probiotics and chronic kidney disease.
abstract: Probiotics are the focus of a thorough investigation as a natural biotreatment due to their various health-promoting effects and inherent ability to fight specific diseases including chronic kidney disease (CKD). Indeed, intestinal microbiota has recently emerged as an important player in the progression and complications of CKD. Because many of the multifactorial physiological functions of probiotics are highly strain specific, preselection of appropriate probiotic strains based on their expression of functional biomarkers is critical. The interest in developing new research initiatives on probiotics in CKD have increased over the last decade with the goal of fully exploring their therapeutic potentials. The efficacy of probiotics to decrease uremic toxin production and to improve renal function has been investigated in in vitro models and in various animal and human CKD studies. However to date, the quality of intervention trials investigating this novel CKD therapy is still lacking. This review outlines potential mechanisms of action and efficacy of probiotics as a new CKD management tool, with a particular emphasis on uremic toxin production and inflammation.
authors.affiliation: Department of Nephrology and Nutrition, Centre Hospitalier Lyon SUD, Carmen, CENS, Univ Lyon, UCBL, Pierre Bénite, France.
authors.forename: Laetitia
authors.initials: L
authors.lastname: Koppe
authors.affiliation: Medical Sciences and Cardiovascular Sciences Graduate Programs, Federal University Fluminense (UFF), Niterói-RJ, Brazil.
authors.forename: Denise
authors.initials: D
authors.lastname: Mafra
authors.affiliation: Department of Nephrology and Nutrition, Centre Hospitalier Lyon SUD, Carmen, CENS, Univ Lyon, UCBL, Pierre Bénite, France.
authors.forename: Denis
authors.initials: D
authors.lastname: Fouque
mesh_terms: D064806:Dysbiosis / Q000209:etiology / Q000378:metabolism; D041981:Gastrointestinal Tract / Q000382:microbiology; D006801:Humans; D007211:Indoles / Q000378:metabolism; D007249:Inflammation / Q000209:etiology; D064307:Microbiota; D010636:Phenols / Q000378:metabolism; D019936:Probiotics / Q000494:pharmacology* / Q000627:therapeutic use; D051436:Renal Insufficiency, Chronic / Q000150:complications / Q000628:therapy*; D014118:Toxins, Biological / Q000378:metabolism*; D014511:Uremia / Q000209:etiology / Q000378:metabolism*
chemical_list: D007211:Indoles; D010636:Phenols; D014118:Toxins, Biological